Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 4/20 | 0.71 |
| ▸ | NAT1 | P18440 | 4/20 | 0.66 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.60 |
| ▸ | MAX | P61244 | 1/20 | 0.60 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 2/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616173 | 1.00 | PTP4A3 (0.71) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL3405858 | 1.00 | PTP4A3 (0.71) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL18102940 | 0.89 | NAT1 (0.66) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL13499577 | 0.86 | NAT1 (0.64) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL18102943 | 0.86 | PTP4A3 (0.75) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL14464055 | 0.83 | PTP4A3 (0.71) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL8174040 | 0.83 | PTP4A3 (0.71) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL8174037 | 0.83 | PTP4A3 (0.71) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL18102858 | 0.83 | PTP4A3 (0.75) | PTP4A3NAT1GSK3BMYCMAX | |
| SCHEMBL14464056 | 0.83 | PTP4A3 (1.00) | PTP4A3NAT1GSK3BMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-2250167-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | Chlorion Pharma, Inc. (CA) | 2010-11-17 | — | — | EP | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | UNIVERSITE LAVAL (CA) | 2009-11-05 | — | — | US | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097695-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | CHLORION PHARMA, INC. (CA) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275538-A1 | ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS | OPRL1, OPRK1, AHR | PTP4A3 1188/4885NAT1 80/4885GSK3B 4008/4885 |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | PTP4A3 4245/4885NAT1 867/4885GSK3B 1070/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | PTP4A3 4245/4885NAT1 867/4885GSK3B 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.